5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC.
Saved in:
| Title: | 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC. |
|---|---|
| Authors: | Velcheti V; Perlmutter Cancer Center, New York University Langone Health, New York, NY., Rai P; Merck & Co., Inc., Rahway, NJ. Electronic address: pragya.rai@merck.com., Kao YH; Merck & Co., Inc., Rahway, NJ., Chirovsky D; Merck & Co., Inc., Rahway, NJ., Nunes AT; Merck & Co., Inc., Rahway, NJ., Liu SV; Department of Medical Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. |
| Source: | Clinical lung cancer [Clin Lung Cancer] 2024 Sep; Vol. 25 (6), pp. 502-508.e3. Date of Electronic Publication: 2024 May 16. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1938-0690 |
|---|---|
| DOI: | 10.1016/j.cllc.2024.05.002 |
